CRChristiane Rordorf

Christiane Rordorf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christiane Rordorf has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lack of Effect of Omeprazole or of an Aluminium Hydroxide/Magnesium Hydroxide Antacid on the Pharmacokinetics of Lumiracoxib

    by Graham Scott, Christine Vinluan Reynolds, Slavica Milosavljev, Wayne Langholff, Magdy Shenouda, Christiane Rordorf

    Objective: To evaluate the effects of multiple doses of omeprazole and of a single dose of an aluminium hydroxide/magnesium hydroxide (Al/Mg) antacid on the single-dose plasma pharmacokinetics of lumiracoxib. Study Design: Open-label, randomised, three-period, crossover study. Population Studied: Healthy subjects aged 18–65 years. Methods: Fourteen subjects who met eligibility criteria were each administered three treatments in random order: (A) lumiracoxib 400mg as a single oral dose; (B) oral omeprazole 20mg once daily for 4 consecutive days, then lumiracoxib 400mg as a single oral dose just prior to oral omeprazole 20mg on day 5; and (C) lumiracoxib 400mg as a single oral dose immediately prior to a 20mL dose of Al/Mg antacid (magnesium hydroxide 800mg and aluminium hydroxide 900mg). The interval between each lumiracoxib dose was 7 days. Analysis of variance was performed to determine whether lumiracoxib alone differed from lumiracoxib plus omeprazole or from lumiracoxib plus Al/Mg antacid for overall exposure (area under the concentration-time curve from zero to infinity [AUC∞]) and peak concentration (Cmax), with treatment sequence, subject, period and treatment as factors. Ratios of geometric means between lumiracoxib plus omeprazole and lumiracoxib plus Al/Mg antacid to lumiracoxib alone (reference) were calculated for AUC∞ and Cmax. If the mean ratios, with 90% CIs, fell within the interval 0.80–1.25, the treatments were considered equivalent. Results: Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching Cmax values (mean ± SD) of 9.24 ± 1.96, 8.81 ± 2.30, and 10.43 ± 3.24 mg/L within 2–3 hours for treatments A, B and C, respectively. AUC∞ was similar for the three treatments (36.75 ± 7.73, 34.88 ± 8.40 and 35.50 ± 5.72 mg • h/L). All ratios of geometric means with 90% CIs fell within the interval used for establishing bioequivalence, except for the Cmax comparison between lumiracoxib plus Al/Mg antacid and lumiracoxib alone, which was 1.11 (0.95, 1.31). Conclusion: Coadministration of lumiracoxib with omeprazole or with an Al/Mg antacid had no clinically significant effect on lumiracoxib single-dose plasma pharmacokinetics. Lumiracoxib can, therefore, be administered concurrently with either of these agents without need for lumiracoxib dosage alteration.


  • Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid

    by Graham Scott, Christiane Rordorf, Christine Reynolds, Jyoti Kalbag, Michael Looby, Slavica Milosavljev, Margaret Weaver, John P. Huff, Dennis A Ruff

    Background umiracoxib is a new cyclo-oxygenase-2 (COX-2) selective inhibitor in development for the treatment of rheumatoid arthritis, osteoarthritis and acute pain.


  • Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects

    by C. Rordorf, N. Kellett, S. Mair, M. Ford, S. Milosavljev, J. Branson, G. Scott

    Summary: Background : Lumiracoxib (Prexige®) is a cyclooxygenase‐2 (COX‐2) selective inhibitor.Aim : To compare the gastroduodenal tolerability of lumiracoxib with placebo and naproxen in a randomized, parallel‐group, double‐blind study.Methods : Sixty‐five healthy male subjects were randomized to receive 8 days' dosing with lumiracoxib 200 mg twice daily (b.d.) (n = 21), placebo (n = 22) or naproxen 500 mg b.d. (n = 22). Endoscopic evaluations of gastric and duodenal mucosae were conducted at baseline and after 8 days' dosing. Serum was assayed for ex‐vivo concentrations of thromboxane B2 (TxB2) to determine cyclooxygenase‐1 (COX‐1) inhibitory activity.Results : Sixty subjects (20 per group) completed the study. No gastroduodenal erosions were observed in subjects receiving lumiracoxib. Thirteen subjects receiving naproxen developed duodenal erosions. At the gastric site, one subject in each of the naproxen and placebo groups had erosions; one subject receiving naproxen also developed a small asymptomatic gastric ulcer. Gastrointestinal adverse events accounted for 42.3% of all adverse events, occurring in 3/21, 4/22 and 6/22 of the lumiracoxib, placebo and naproxen groups, respectively. TxB2 levels were similar for patients receiving placebo or lumiracoxib, but were reduced by > 95% in patients receiving naproxen, compared with placebo.Conclusions : Multiple doses of lumiracoxib resulted in gastroduodenal tolerability similar to placebo and superior to naproxen.